Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder

被引:61
作者
Palatnik, A
Frolov, K
Fux, M
Benjamin, J
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Minist Hlth, Mental Hlth Ctr, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr,Kupat Holim Sick Fund, Dept Psychiat, Beer Sheva, Israel
关键词
D O I
10.1097/00004714-200106000-00014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Only 70% of patients respond to current treatments for panic disorder, and many discontinue drugs because of side effects. myo-Inositol, a natural isomer of glucose and a precursor for the second-messenger phosphatidyl-inositol system, has previously been found superior to placebo in the treatment of depression, panic disorder, and obsessive-compulsive disorder (OCD), but a direct comparison with an established drug has never been performed. A double-blind, controlled, random-order crossover study was undertaken to compare the effect of inositol with that of fluvoxamine in panic disorder, Twenty patients completed 1 month of inositol up to 18 g/day and I month of fluvoxamine up to 150 mg/day. Improvements on Hamilton Rating Scale for Anxiety scores, agoraphobia scores, and Clinical Global Impressions Scale scores were similar for both treatments. In the first month, inositol reduced the number of panic attacks per week (mean and SI)) by 4.0 (2) compared with a reduction of 2.4 (2) with fluvoxamine (p = 0.049), Nausea and tiredness were more common with fluvoxamine (p = 0.02 and p = 0.01, respectively). Because inositol is a natural compound with few known side effects, it is attractive to patients who are ambivalent about taking psychiatric medication. Continuing reports of inositol's efficacy in the treatment of depression, panic disorder, and OCD should stimulate replication studies.
引用
收藏
页码:335 / 339
页数:5
相关论文
共 31 条
[21]   BRIEF STANDARD SELF-RATING FOR PHOBIC PATIENTS [J].
MARKS, IM ;
MATHEWS, AM .
BEHAVIOUR RESEARCH AND THERAPY, 1979, 17 (03) :263-267
[22]  
MAVISSAKALIAN MR, 1995, AM J PSYCHIAT, V152, P673
[23]   PANIC ATTACKS - A NEUROCHEMICAL OVERVIEW OF MODELS AND MECHANISMS [J].
NUTT, D ;
LAWSON, C .
BRITISH JOURNAL OF PSYCHIATRY, 1992, 160 :165-178
[24]   ANXIETY PSYCHOPATHOLOGY PREDICTIVE OF OUTCOME IN PATIENTS WITH PANIC DISORDER AND DEPRESSION TREATED WITH IMIPRAMINE, ALPRAZOLAM AND PLACEBO [J].
POLLACK, MH ;
OTTO, MW ;
SACHS, GS ;
LEON, A ;
SHEAR, MK ;
DELTITO, JA ;
KELLER, MB ;
ROSENBAUM, JF .
JOURNAL OF AFFECTIVE DISORDERS, 1994, 30 (04) :273-281
[25]  
Pollack MH, 1997, J CLIN PSYCHIAT, V58, P57
[26]   MYOINOSITOL REDUCES SEROTONIN (5-HT2) RECEPTOR-INDUCED HOMOLOGOUS AND HETEROLOGOUS DESENSITIZATION [J].
RAHMAN, S ;
NEUMAN, RS .
BRAIN RESEARCH, 1993, 631 (02) :349-351
[27]   Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia [J].
Sharp, DM ;
Power, KG ;
Simpson, RJ ;
Swanson, V ;
Moodie, E ;
Anstee, JA ;
Ashford, JJ .
JOURNAL OF ANXIETY DISORDERS, 1996, 10 (04) :219-242
[28]  
SHEAR MK, 1994, ARCH GEN PSYCHIAT, V51, P346
[29]  
Shear MK, 1997, J CLIN PSYCHIAT, V58, P38
[30]   PHOBIC SYMPTOMS AS PREDICTORS OF NONRESPONSE TO DRUG-THERAPY IN PANIC DISORDER PATIENTS (A PRELIMINARY-REPORT) [J].
SLAAP, BR ;
VANVLIET, IM ;
WESTENBERG, HGM ;
DENBOER, JA .
JOURNAL OF AFFECTIVE DISORDERS, 1995, 33 (01) :31-38